Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last C$0.07 CAD
Change Today 0.00 / 0.00%
Volume 31.0K
ICO On Other Exchanges
As of 2:28 PM 10/9/15 All times are local (Market data is delayed by at least 15 minutes).

ico therapeutics inc (ICO) Snapshot

Previous Close
Day High
Day Low
52 Week High
04/23/15 - C$0.14
52 Week Low
12/29/14 - C$0.03
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for ICO THERAPEUTICS INC (ICO)

Related News

No related news articles were found.

ico therapeutics inc (ICO) Related Businessweek News

View More BusinessWeek News

ico therapeutics inc (ICO) Details

iCo Therapeutics Inc., a biotechnology company, focuses on the identification, development, and commercialization of drug candidates to treat sight and life threatening diseases. Its in-licensed product candidates include iCo-008 (Bertilimumab), a human monoclonal antibody, which is in Phase II clinical trial to treat sight threatening ocular allergies and various systemic indications; and Oral Amphotericin B Delivery System that is in pre-clinical stage used for the treatment of systemic fungal infections in immune-compromised patients, such as in HIV/AIDS, cancer, transplant recipients, diabetics, etc., as well as certain parasitical infections. iCo Therapeutics Inc. has partnership arrangements with Isis Pharmaceuticals, Inc.; MedImmune Limited; Immune Pharmaceuticals Inc.; AstraZeneca; and the University of British Columbia. iCo Therapeutics Inc. was founded in 2005 and is headquartered in Vancouver, Canada.

5 Employees
Last Reported Date: 04/27/15
Founded in 2005

ico therapeutics inc (ICO) Top Compensated Officers

Co-Founder, Chief Executive Officer, Presiden...
Total Annual Compensation: C$312.0K
Chief Financial Officer and Corporate Secreta...
Total Annual Compensation: C$168.0K
Chief Medical Officer
Total Annual Compensation: C$192.0K
Compensation as of Fiscal Year 2014.

ico therapeutics inc (ICO) Key Developments

iCo Therapeutics Announces Earnings Results for the Second Quarter Ended June 30, 2015

iCo Therapeutics announced earnings results for the second quarter ended June 30, 2015. For the quarter, the company incurred a total comprehensive loss of CAD 738,607 or loss per share of CAD 0.01 compared to total comprehensive loss of CAD 2,982,109 or loss per share of CAD 0.04 for the quarter ended June 30, 2014, representing a reduced loss of CAD 2,243,502. This decrease is primarily a result of the both the sale and change in value of investment in Immune Therapeutics Inc., as well completion of iCO-007 iDEAL trial.

iCo Therapeutics Inc. Announces Earnings Results for the First Quarter Ended March 31, 2015

iCo Therapeutics Inc. announced earnings results for the first quarter ended March 31, 2015. For the quarter, the company incurred a total comprehensive loss of $252,397 (loss per share of $0.00), compared to total comprehensive earnings of $1,365,068 (earnings per share of $0.02) for the quarter ended March 31, 2014, representing an increased loss of $1,617,465. The increase is primarily a result of changes related to holdings in Immune Pharmaceuticals Inc.

iCo Therapeutics Inc. Reports Financial Results for the Year Ended December 31, 2014

iCo Therapeutics Inc. reported financial results for the year ended December 31, 2014. The company incurred a total comprehensive loss of CAD,079,657 for the year ended December 31, 2014 compared to a total loss of CAD 5,918,965 for the year ended 2013, representing a decrease of CAD 3,839,308. The decrease in its net and comprehensive loss was principally caused by a reduction of clinical trial costs associated with the iDEAL study.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ICO:CN C$0.07 CAD 0.00

ICO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ICO.
View Industry Companies

Industry Analysis


Industry Average

Valuation ICO Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 1.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ICO THERAPEUTICS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at